Gapping up
In reaction to strong earnings/guidance: LEN +3.7%
M&A news: ASEI +12.6% (to be acquired by OSI Systems (OSIS) for $37.00/share in cash, or ~$269 mln), NSR +4.1% (announces intention to separate into two independent and publicly traded companies)
Select EU financial related names showing strength: SAN +2.5%, BCS+2.4%, PUK +2.2%, DB +2%, ING +2%, RBS +1.9%, LYG +1.5%, CS+1.4%
Other news: CDXC +9.2% (responds to recent report of short sellers; co exploring options in response to 'attack' ), OPK +7.8% (confirms FDA approval for RAYALDEE; U.S. launch planned for H2 of 2016),IMPV +7.7% (Elliott Associates disclosed a 9.8% active stake, confirming reports it has acquired a position. Elliott said it has initiated dialogue with management and the Board on ways to increase shareholder value), RDHL +6.8% (positive final results with primary and secondary endpoints met in phase 1 study with Yeliva in advanced solid tumors), CYRN +6.1% (Thomson Reuters (TRI) announced a strategic partnership with CYREN (CYRN).g), GWPH+3.5% (selects infantile spasms as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program), MITK+3.3% (issued patent by the USPTO for its unique system for processing and extracting content from the image of a driver license captured using a mobile device), UAL +3.1% (Outlines value-driving initiatives), KBH +2.8% (in sympathy with LEN), GBT +2% (prices upsized offering of 6.4 mln shares of its common stock at $18.75/share), GEVO +1.8% (Intracoastal Capital discloses 3.1% passive stake)
Analyst comments: RUN +1.8% (initiated with an Outperform at Oppenheimer), ERIC +1.7% (upgraded to Neutral from Sell at Goldman), MRO +1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
In reaction to strong earnings/guidance: LEN +3.7%
M&A news: ASEI +12.6% (to be acquired by OSI Systems (OSIS) for $37.00/share in cash, or ~$269 mln), NSR +4.1% (announces intention to separate into two independent and publicly traded companies)
Select EU financial related names showing strength: SAN +2.5%, BCS+2.4%, PUK +2.2%, DB +2%, ING +2%, RBS +1.9%, LYG +1.5%, CS+1.4%
Other news: CDXC +9.2% (responds to recent report of short sellers; co exploring options in response to 'attack' ), OPK +7.8% (confirms FDA approval for RAYALDEE; U.S. launch planned for H2 of 2016),IMPV +7.7% (Elliott Associates disclosed a 9.8% active stake, confirming reports it has acquired a position. Elliott said it has initiated dialogue with management and the Board on ways to increase shareholder value), RDHL +6.8% (positive final results with primary and secondary endpoints met in phase 1 study with Yeliva in advanced solid tumors), CYRN +6.1% (Thomson Reuters (TRI) announced a strategic partnership with CYREN (CYRN).g), GWPH+3.5% (selects infantile spasms as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program), MITK+3.3% (issued patent by the USPTO for its unique system for processing and extracting content from the image of a driver license captured using a mobile device), UAL +3.1% (Outlines value-driving initiatives), KBH +2.8% (in sympathy with LEN), GBT +2% (prices upsized offering of 6.4 mln shares of its common stock at $18.75/share), GEVO +1.8% (Intracoastal Capital discloses 3.1% passive stake)
Analyst comments: RUN +1.8% (initiated with an Outperform at Oppenheimer), ERIC +1.7% (upgraded to Neutral from Sell at Goldman), MRO +1% (upgraded to Overweight from Equal-Weight at Morgan Stanley)